Aptinyx Inc logo

APTX - Aptinyx Inc Share Price

$1.99 -0.1  -2.5%

Last Trade - 03/04/20

Sector
Healthcare
Size
Small Cap
Market Cap £73.9m
Enterprise Value £-6.72m
Revenue £2.99m
Position in Universe 3962nd / 6308
Bullish
Bearish
Unlock APTX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

APTX Revenue Unlock APTX Revenue

Net Income

APTX Net Income Unlock APTX Revenue

Normalised EPS

APTX Normalised EPS Unlock APTX Revenue

PE Ratio Range

APTX PE Ratio Range Unlock APTX Revenue

Dividend Yield Range

APTX Dividend Yield Range Unlock APTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
APTX EPS Forecasts Unlock APTX Revenue
Profile Summary

Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated June 24, 2015
Public Since June 21, 2018
No. of Shareholders: 132
No. of Employees: 43
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 45,534,432
Free Float (0.0%)
Eligible for
ISAs
SIPPs
APTX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for APTX
Upcoming Events for APTX
Monday 11th May, 2020 Estimate
Q1 2020 Aptinyx Inc Earnings Release
Thursday 14th May, 2020 Estimate
Aptinyx Inc Annual Shareholders Meeting
Monday 10th August, 2020 Estimate
Q2 2020 Aptinyx Inc Earnings Release
Similar to APTX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.